NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Syros Pharmaceuticals Inc (NASDAQ:SYRS) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.01. The firm earned $0.56 million during the quarter, compared to analysts' expectations of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. View Syros Pharmaceuticals' Earnings History.

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals.

7 analysts have issued 12 month target prices for Syros Pharmaceuticals' shares. Their forecasts range from $9.00 to $18.00. On average, they expect Syros Pharmaceuticals' share price to reach $13.83 in the next year. This suggests a possible upside of 91.1% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.

Media stories about SYRS stock have been trending extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Syros Pharmaceuticals earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Syros Pharmaceuticals.

Syros Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,340,000 shares, an increase of 30.0% from the December 31st total of 1,800,000 shares. Based on an average daily trading volume, of 479,200 shares, the short-interest ratio is presently 4.9 days. Currently, 7.6% of the shares of the company are short sold. View Syros Pharmaceuticals' Current Options Chain.

Some companies that are related to Syros Pharmaceuticals include Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS), Myovant Sciences (MYOV), Athenex (ATNX), ZEALAND PHARMA/S (ZEAL), Rocket Pharmaceuticals (RCKT), Karyopharm Therapeutics (KPTI), Enanta Pharmaceuticals (ENTA), Opko Health (OPK) and Portola Pharmaceuticals (PTLA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Global Blood Therapeutics (GBT), Galmed Pharmaceuticals (GLMD), ImmunoGen (IMGN) and Viking Therapeutics (VKTX).

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYRS stock can currently be purchased for approximately $7.24.

Syros Pharmaceuticals has a market capitalization of $307.27 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.

The official website for Syros Pharmaceuticals is http://www.syros.com/.

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]